Xilio Therapeutics | 10-Q: Q2 2024 Earnings Report
Xilio Therapeutics | 8-K: Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
Xilio Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Frankenfield Christopher James
Xilio Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Takeda Pharmaceutical Company Limited(4%),Takeda Ventures, Inc(4%)
Xilio Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Bonstein Sara
Xilio Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Xu Yuan
Xilio Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director ROSS ROBERT W.
Xilio Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Rossi Christina
Xilio Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Clancy Paul J
Xilio Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Curran Daniel J.
Xilio Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Shannon James Samuel
Xilio Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Brennan Aoife
Xilio Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Shannon James Samuel
Xilio Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Brennan Aoife
Xilio Therapeutics | 8-K: Current report
Xilio Therapeutics | 8-K: Current report
Xilio Therapeutics | 10-Q: Q1 2024 Earnings Report
Xilio Therapeutics | 8-K: Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
Xilio Therapeutics | EFFECT: Others
Xilio Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Russo Rene
No Data